Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

ed to be in a range of $20 to $25 million.  The company anticipates that full-year revenue will be at or slightly above the high end of the range.
  • R&D expense: currently anticipated to be in a range of $90 to $105 million.  The company anticipates that full-year R&D expenses will be at the high end of the range.
  • SG&A expense: currently anticipated to be in a range of $110 to $130 million.  The company anticipates that full-year SG&A expenses will be at the low end of the range.
  • Total Operating Expenses (R&D and SG&A): currently anticipated to be in a range of $200 to $235 million. 
  • Conference Call and Webcast Details
    InterMune will host a live webcast of a conference call today at 4:30 p.m. EST to discuss business highlights and financial results for the third quarter and first nine months of 2012.  Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 21610043.  A replay of the webcast and teleconference will be available approximately three hours after the call.

    To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

    A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering conference ID# 21610043.  The webcast will remain available on the company's website until the next earnings call.

    About InterMune
    InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, the company is focused on therapies for the tr
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune To Release Third Quarter Financial Results On November 7
    2. InterMune To Present At JMP Securities Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune to Present at J. P. Morgan Healthcare Conference
    5. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
    8. Patient Safety Technologies Reports Third Quarter 2012 Results
    9. PDI Reports 2012 Third Quarter Financial Results
    10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    11. Neurocrine Biosciences Reports Third Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
    (Date:12/22/2014)... 22, 2014 The Center for ... of technical training across the life sciences industry, has ... (SCDM) to provide the organization's members with discounted ... access to the more than 350 sessions across 80 ... 10% off when registering for a public course ...
    (Date:12/22/2014)... Dec. 22, 2014  Alternative Energy & Environmental ... has signed a letter of intent to acquire ... and patented a nanotechnology-based development platform used to ... enable rapid on-site collection and testing to identify ... issues in an immediate, non-invasive and cost-effective manner. ...
    (Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
    Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
    ... Tandem Labs, a leading contract,research organization ... services to the pharmaceutical,industry, announced that it ... 4000(TM) LC/MS/MS systems for its New England ... facility,s current triple,quadrupole LC/MS/MS capacity, allowing it ...
    ... Identify Pathways and ... Metabolomic Data, REDWOOD CITY, Calif., Oct. 9 ... to help life science researchers,generate insights from biological ... within Ingenuity,Pathways Analysis to help researchers understand metabolomics ...
    ... SAN DIEGO, Oct. 8 SGX Pharmaceuticals, Inc.,(Nasdaq: ... on October 11,2007, at 1:00 p.m. Pacific Daylight Time. ... will provide an overview of the,Company,s oncology pipeline. The ... the Palace Hotel in San Francisco. A live ...
    Cached Biology Technology:Tandem Labs' New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England 2Ingenuity Systems Launches New Metabolomics Solution Within IPA 2
    (Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
    (Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
    (Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
    Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
    ... identified a novel function for an enzyme that plays a ... also known as ARDS. The finding offers a new ... and injury. The research will be published in the journal ... 29. ARDS is an often fatal complication of bacterial ...
    ... ripen in our gardens, we watch them turn gradually ... tasty fruits. This familiar and seemingly commonplace transformation ... well-regulated albeit highly complex manner. For generations, agriculturalists ... flavor, shelf-life, and nutrient composition, more or less, one ...
    ... in French and Spanish . ... States are joining forces to protect and conserve the ... America,s shared environment. Although the monarch butterfly ( ... its unique multigenerational migration spanning the continent is considered ...
    Cached Biology News:UIC researchers make promising finding in severe lung disease 2The 21st century tomato 2The 21st century tomato 3Continental plan to protect the monarch's migratory journey 2
    ... SpliceArray is a new generation of ... SpliceArray Service enables you to rapidly elucidate ... to be relevant for drug discovery. The ... patented probe design and customized analysis with ...
    ... angle system, 220-240 V, is used to resolve ... fragments by pulsed field gel electrophoresis (PFGE). The ... pump, 14 x 13 cm casting stand with ... thick comb, screened cap, disposable plug molds, 12 ...
    ... inhibits protein synthesis. Acts by inhibiting ... Reported to induce apoptosis in a ... cells, Jurkat cells, ventricular myocytes, and ... and immediate early gene induction. Selective ...
    Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
    Biology Products: